Neurobiology of Aging
Volume 28, Issue 4 , Pages 485-496 , April 2007

Peripheral T cells overexpress MIP-1α to enhance its transendothelial migration in Alzheimer's disease

Received 3 October 2005 ,Revised 14 February 2006 ,Accepted 16 February 2006.

References 

  1. Andjelkovic AV, Pachter JS. Characterization of binding sites for chemokines MCP-1 and MIP-1alpha on human brain microvessels. J Neurochem. 2000;75(5):1898–1906
  2. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916–919
  3. Berger O, Gan X, Gujuluva C, Burns AR, Sulur G, Stins M, et al. CXC and CC chemokine receptors on coronary and brain endothelia. Mol Med. 1999;5(12):795–805
  4. Citi S, Cordenonsi M. Tight junction proteins. Biochim Biophys Acta. 1998;1448(1):1–11
  5. Davatelis G, Tekamp-Olson P, Wolpe SD, Hermsen K, Luedke C, Gallegos C, et al. Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokine properties. J Exp Med. 1988;167(6):1939–1944
  6. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, et al. Neuroinflammation in Alzheimer's disease and prion diseases. Glia. 2002;40(2):232–239
  7. Eikelenboom P, Rozemuller JM, Kraal G, Stam FC, McBride PA, Bruce ME, et al. Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60(5):329–336
  8. Folstein MF, Folstein SE, McHugh PR. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198
  9. Giri RK, Rajagopal V, Shahi S, Zlokovic BV, Kalra VK. Mechanism of amyloid peptide induced CCR5 expression in monocytes and its inhibition by siRNA for Egr-1. Am J Physiol Cell Physiol. 2005;289(2):C264–C276
  10. Grab DJ, Nikolskaia O, Kim YV, Lonsdale-Eccles JD, Ito S, Hara T, et al. African trypanosome interactions with an in vitro model of the human blood–brain barrier. J Parasitol. 2004;90(5):970–979
  11. Hara T, Wakatsuki S, Ozaki S, Abe M, Kosaka M. Primary adult T-cell leukemia/lymphoma of bone. Int J Hematol. 2004;79(2):157–160
  12. Hardy J, Selkoe DJ. The amyloid hyothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356
  13. Huang SH, Chen YH, Fu Q, Stins M, Wang Y, Wass C, et al. Identification and characterization of an Escherichia coli invasion gene locus, ibeB, required for penetration of brain microvascular endothelial cells. Infect Immun. 1999;67(5):2103–2109
  14. Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier. Trends Neurosci. 2001;24(12):719–725
  15. Itagaki S, McGeer PL, Akiyama H. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci Lett. 1988;91(3):259–264
  16. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408(6815):979–982
  17. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol. 1995;155(10):5003–5010
  18. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem. 1999;274(14):9617–9626
  19. Lukacs NW, Chensue SW, Smith RE, Strieter RM, Warmington K, Wilke C, et al. Production of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 a by inflammatory granuloma fibroblasts. Am J Pathol. 1994;144(4):711–718
  20. Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science. 1999;285(5429):895–898
  21. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430(7000):631–639
  22. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944
  23. Mennicken F, Maki R, de Souza EB, Quirion R. Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. Trends Pharmacol Sci. 1999;20(2):73–78
  24. Monsonego A, Imitola J, Zota V, Oida T, Weiner HL. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid b-peptide presentation to Th1 cells. J Immunol. 2003;171(5):2216–2224
  25. Monsonego A, Weiner HL. Immunotherapeutic approaches to Alzheimer's disease. Science. 2003;302(5646):834–838
  26. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest. 2003;112(3):415–422
  27. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408(6815):982–985
  28. Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol. 2004;36(1):35–38
  29. Parmal P, Basuroy S, Li CH, Naren AP, Rao RK. Role of phosphatidylinositol 3-kinase in oxidative stress-induced disruption of tight junctions. J Biol Chem. 2003;278(49):49239–49245
  30. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci. 1998;21:479–505
  31. Ransohoff RM, Kivisäkk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev. 2003;3(7):569–581
  32. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. 1988;9(4):339–349
  33. Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid b peptide. Glia. 2002;40(2):260–269
  34. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173–177
  35. Séguin R, Biernacki K, Prat A, Wosik K, Kim HJ, Blain M, et al. Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. Glia. 2003;42(1):36–45
  36. Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci. 2004;24(28):6277–6282
  37. Smits HA, Rijsmus A, van Loon JH, Wat JW, Verhoef J, Boven LA, et al. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol. 2002;127(1–2):160–168
  38. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV. Potential role of MCP-1 in endothelial cell tight junction ‘opening’: signaling via Rho and Rho kinase. J Cell Sci. 2003;116(Pt22):4615–4628
  39. Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, et al. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol. 2002;124(1–2):83–92
  40. Townsend KP, Town T, Mori T, Lue LF, Shytle D, Sanberg PR, et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur J Immunol. 2005;35(3):901–910
  41. Walker DG, Lue LF, Beach TG. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging. 2001;22(6):957–966
  42. Wekerle H. T cell autoimmunity in the central nervous system. Intervirology. 1993;35(1–4):95–100
  43. Wojciak-Stothard B, Ridley AJ. Rho GTPase and the regulation of endothelial permeability. Vascular Pharmacol. 2002;39(4–5):187–199
  44. Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, et al. Macrophages secrete a novel hepartin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med. 1988;167(2):570–581
  45. Wong D, Dorovini-Zis K, Vincent SR. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood–brain barrier. Exp Neurol. 2004;190(2):446–455
  46. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the gamma-secretase inhibitor LY-411, 575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279(13):12876–12882
  47. Xia MQ, Hyman BT. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol. 1999;5(1):32–41
  48. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol. 1998;153(1):31–37

PII: S0197-4580(06)00077-7

doi: 10.1016/j.neurobiolaging.2006.02.013

Neurobiology of Aging
Volume 28, Issue 4 , Pages 485-496 , April 2007

Article Tools

* Image Usage & Resolution